DOE Brookhaven & Texas A&M Use Uncertainty to Boost AI
Why it matters: Pharma firms can evaluate ~10× more AI‑generated candidates per month, shaving weeks off early‑stage drug discovery.
- DOE Brookhaven National Laboratory integrates uncertainty quantification into its generative AI pipelines (per source)
- Texas A&M University partners to fine‑tune the models, adding Bayesian methods that flag low‑confidence predictions (per source)
- AI‑engineered molecular design now outputs diverse candidate structures with explicit confidence metrics, improving screening efficiency (per source)
DOE’s Brookhaven National Lab and Texas A&M are turning prediction uncertainty into a design lever for AI‑driven molecular discovery, letting models generate candidate compounds together with confidence scores. By quantifying what they don’t know, the researchers boost hit‑rates and cut the time needed to move from concept to lab‑ready molecules.
